Seres Therapeutics Share Price Today

Seres to present SER-428 preclinical data showing pathogen reduction

Seres Therapeutics to present SER-428 preclinical data at IDWeek 2026. Preclinical models showed up to 1,000-fold reduction in key pathogens. Liquid formulation designed for critically ill patients unable to take capsules. Phase 1b trial design underway pending external funding.

Seres Therapeutics grants 4,200 inducement options to new hires

Seres Therapeutics granted 4,200 stock options to two new employees. Options have an exercise price of $5.72 per share. Awards vest 25% after one year and 6.25% quarterly thereafter. Grants comply with Nasdaq Listing Rule 5635(c)(4).

Seres Therapeutics to present at H.C. Wainwright investment conference

Seres Therapeutics management to present at H.C. Wainwright conference on September 15, 2026. Presentation scheduled for 2 p.m. ET in New York with live webcast available. SER-155 pipeline asset is Phase 2 ready pending funding for transplant infection prevention. Company evaluating Phase 2 study design for irEC after promising investigator-sponsored trial results.

Seres H1FY26 Results: Revenue Rises To RMB 57.493 Billion

Seres Group posted H1FY26 revenue of RMB 57.493 billion, driven by a 10.2% YoY rise in AITO deliveries. R&D spending jumped 34.8% to RMB 7.007 billion, supporting tech integration in its luxury NEV portfolio. The company also executed over RMB 587 million in share repurchases, maintaining a low-debt balance sheet.

Seres Therapeutics files $300M shelf prospectus for equity and debt

Seres Therapeutics, Inc. filed a shelf prospectus to potentially raise up to $300 million through the issuance of common stock, preferred stock, debt securities, warrants, and units. The filing allows for flexible distribution methods, including underwritten offerings or direct sales. Specific terms, pricing, and volumes for any future issuances will be disclosed in subsequent prospectus supplements, providing the company with ongoing access to capital markets.

Seres Therapeutics reports positive SER-155 irEC study results

Seres Therapeutics Inc. announced positive topline results from a study evaluating SER-155 in patients with immune-related enterocolitis (irEC). The study demonstrated that 80% of participants achieved an immunosuppressive-free clinical response at Day 15, the primary endpoint. SER-155 was well tolerated with no drug-related serious adverse events observed through Day 43.